Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 16Gynecologic 2Thoracic 1Sarcoma 1Head & Neck 1Genitourinary 1

Conditions

Sarcoma 25Central Nervous System Neoplasms 18Astrocytoma 15Gliosarcoma 14Glioblastoma 14Ovarian Neoplasms 12Oligodendroglioma 10Neuroectodermal Tumors, Primitive, Peripheral 10Brain Neoplasms 10Osteosarcoma 9Neuroblastoma 9Testicular Neoplasms 8Glioma 8Dendritic Cell Sarcoma, Interdigitating 8Medulloblastoma 7Breast Neoplasms 7Choroid Plexus Neoplasms 6Carcinosarcoma 6Burkitt Lymphoma 6Wilms Tumor 5Testicular Germ Cell Tumor 5Stomach Neoplasms 5Rhabdoid Tumor 5Optic Nerve Glioma 5Neoplasms 5Lymphoma, Non-Hodgkin 5Lymphoma, Large B-Cell, Diffuse 5Kidney Neoplasms 5Head and Neck Neoplasms 5Retinoblastoma 4

Interventions

spartalizumab 2tislelizumab 1ribociclib 1brivanib 1Fulvestrant 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma Of Esophagus × Carboplatin × Sarcoma × Clear all
NCT05252416 2025-11-28

(VELA) Study of BLU-222 in Advanced Solid Tumors

Blueprint Medicines Corporation

Phase 1 Terminated
50 enrolled
GastrointestinalGynecologicSarcoma

Adenocarcinoma Of Esophagus, Carcinosarcoma, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡